Philippe Colin
Overview
Explore the profile of Philippe Colin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
2461
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khuu A, Verreault M, Colin P, Tran H, Idbaih A
Cells
. 2024 Nov;
13(22).
PMID: 39594617
Antisense oligonucleotides (ASOs) are promising drugs capable of modulating the protein expression of virtually any target with high specificity and high affinity through complementary base pairing. However, this requires a...
2.
Virbel G, Mallereau C, Lhermitte B, Feuvret L, Biau J, Clement L, et al.
Cancer Radiother
. 2024 Aug;
28(4):365-372.
PMID: 39095224
Purpose: Neurocytomas represent 0.25 to 0.5% of primary brain tumours and are mainly found in young adults. These tumours have neuronal differentiation. The cornerstone treatment is neurosurgery. The efficacy of...
3.
Charlot K, Coca M, Colin P, Tavard B, Bourrilhon C
Physiol Behav
. 2024 Feb;
277:114497.
PMID: 38364985
Introduction: Limiting body mass loss during military expeditions/training in the cold by providing rations containing easy-to-use, highly palatable, and familiar foods is feasible, but the bulk/weight is too high to...
4.
Ringe R, Colin P, Ozorowski G, Allen J, Yasmeen A, Seabright G, et al.
PLoS Pathog
. 2023 Oct;
19(10):e1011601.
PMID: 37903160
Neutralizing antibodies (NAbs) to multiple epitopes on the HIV-1-envelope glycoprotein (Env) have been isolated from infected persons. The potency of NAbs is measured more often than the size of the...
5.
Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al.
J Clin Oncol
. 2023 Jun;
41(19):3469-3477.
PMID: 37379692
Purpose: In metastatic colorectal cancer, phase III studies have demonstrated the superiority of fluorouracil (FU) with leucovorin (LV) in combination with irinotecan or oxaliplatin over FU + LV alone. This...
6.
Thomas-Joulie A, Houillier C, Antoni D, Crehange G, Jouglar E, Colin P, et al.
Acta Oncol
. 2023 Jun;
62(6):648-656.
PMID: 37338525
Introduction: The objective of this study was a multicentric evaluation of professional practices, analyzing the irradiation technique itself and its impact on survival and recurrence sites, in primary central nervous...
7.
Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization
Colin P, Ringe R, Yasmeen A, Ozorowski G, Ketas T, Lee W, et al.
Retrovirology
. 2023 May;
20(1):9.
PMID: 37244989
Background: Neutralizing antibodies (NAbs) protect against HIV-1 acquisition in animal models and show promise in treatment of infection. They act by binding to the viral envelope glycoprotein (Env), thereby blocking...
8.
Ortholan C, Colin P, Serrano B, Bouet T, Garnier N, le Guyader M, et al.
J Headache Pain
. 2023 May;
24(1):51.
PMID: 37170187
Background: This study compares the outcome of patients suffering from medically refractory classical trigeminal neuralgia (TN) after treatment with radiosurgery using two different shot sizes (5- and 6-mm). Methods: All...
9.
Rodier C, Kanagaratnam L, Morland D, Herbin A, Durand A, Chauchet A, et al.
Hemasphere
. 2023 May;
7(5):e861.
PMID: 37125257
Patients (pts) with asymptomatic low-burden follicular lymphoma (FL) are usually observed at diagnosis. Time to lymphoma treatment (TLT) initiation can however be very heterogeneous and risk factors of progression are...
10.
Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization
Colin P, Ringe R, Yasmeen A, Ozorowski G, Ketas T, Lee W, et al.
Res Sq
. 2023 Mar;
PMID: 36865101
Neutralizing antibodies (NAbs) protect against HIV-1 acquisition in animal models and show promise in treatment of infection. They act by binding to the viral envelope glycoprotein (Env), thereby blocking its...